Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Stephen Daniel Wiviott, M.D.

TitleAssociate Professor of Medicine
InstitutionBrigham and Women's Hospital
DepartmentMedicine
AddressHarvard University/BWH -1st floor
350 Longwood Ave, The Galleria
Boston MA 02115
Phone617/732-5500
Fax617/734-7329

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2013 Nov 28; 369(22):2093-104.
    View in: PubMed
  2. Ojeifo O, Wiviott SD, Antman EM, Murphy SA, Udell JA, Bates ER, Mega JL, Sabatine MS, O'Donoghue ML. Concomitant Administration of Clopidogrel With Statins or Calcium-Channel Blockers: Insights From the TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38). JACC Cardiovasc Interv. 2013 Dec; 6(12):1275-81.
    View in: PubMed
  3. Kohli P, Udell JA, Murphy SA, Cannon CP, Antman EM, Braunwald E, Wiviott SD. Discharge Aspirin Dose and Clinical Outcomes in Patients With Acute Coronary Syndromes Treated With Prasugrel Versus Clopidogrel: An Analysis From the TRITON-TIMI 38 Study (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38). J Am Coll Cardiol. 2014 Jan 28; 63(3):225-32.
    View in: PubMed
  4. Desai NR, Peterson ED, Chen AY, Wiviott SD, Sabatine MS, Alexander KP, Roe MT, Shah BR. Balancing the risk of mortality and major bleeding in the treatment of NSTEMI patients - A report from the National Cardiovascular Data Registry. Am Heart J. 2013 Dec; 166(6):1043-1049.e1.
    View in: PubMed
  5. Patel JH, Gupta R, Roe MT, Peng SA, Wiviott SD, Saucedo JF. Influence of Presenting Electrocardiographic Findings on the Treatment and Outcomes of Patients With Non-ST-Segment Elevation Myocardial Infarction. Am J Cardiol. 2014 Jan 15; 113(2):256-61.
    View in: PubMed
  6. Mogabgab O, Wiviott SD, Cannon CP, Sloan S, Sabatine MS, Antman EM, Braunwald E, Giugliano RP. Circadian Variation of Stent Thrombosis and the Effect of More Robust Platelet Inhibition: A Post Hoc Analysis of the TRITON-TIMI 38 Trial. J Cardiovasc Pharmacol Ther. 2013 Nov; 18(6):555-9.
    View in: PubMed
  7. Steg PG, Mehta SR, Pollack CV, Bode C, Cohen M, French WJ, Hoekstra J, Rao SV, Ruzyllo W, Ruiz-Nodar JM, Sabaté M, Widimsky P, Kiss RG, Navarro Estrada JL, Hod H, Kerkar P, Guneri S, Sezer M, Ruda M, Nicolau JC, Cavallini C, Ebrahim I, Petrov I, Kim JH, Jeong MH, Ramos Lopez GA, Laanmets P, Kovar F, Gaudin C, Fanouillere KC, Minini P, Hoffman EB, Moryusef A, Wiviott SD, Sabatine MS. Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial. JAMA. 2013 Sep 18; 310(11):1145-55.
    View in: PubMed
  8. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013 Oct 3; 369(14):1317-26.
    View in: PubMed
  9. Wiviott SD, White HD, Ohman EM, Fox KA, Armstrong PW, Prabhakaran D, Hafley G, Lokhnygina Y, Boden WE, Hamm C, Clemmensen P, Nicolau JC, Menozzi A, Ruzyllo W, Widimsky P, Oto A, Leiva-Pons J, Pavlides G, Winters KJ, Roe MT, Bhatt DL. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet. 2013 Aug 17; 382(9892):605-13.
    View in: PubMed
  10. Mega JL, Braunwald E, Wiviott SD, Murphy SA, Plotnikov A, Gotcheva N, Ruda M, Gibson CM. Comparison of the Efficacy and Safety of Two Rivaroxaban Doses in Acute Coronary Syndrome (from ATLAS ACS 2-TIMI 51). Am J Cardiol. 2013 Aug 15; 112(4):472-8.
    View in: PubMed
  11. Diercks DB, Kontos MC, Hollander JE, Mumma BE, Holmes DN, Wiviott S, Saucedo JF, de Lemos JA. ED administration of thienopyridines in non-ST-segment elevation myocardial infarction: results from the NCDR. Am J Emerg Med. 2013 Jul; 31(7):1005-11.
    View in: PubMed
  12. Truong QA, Hayden D, Woodard PK, Kirby R, Chou ET, Nagurney JT, Wiviott SD, Fleg JL, Schoenfeld DA, Udelson JE, Hoffmann U. Sex Differences in the Effectiveness of Early Coronary Computed Tomographic Angiography Compared With Standard Emergency Department Evaluation for Acute Chest Pain: The Rule-Out Myocardial Infarction With Computer-Assisted Tomography (ROMICAT)-II Trial. Circulation. 2013 Jun 25; 127(25):2494-502.
    View in: PubMed
  13. Scirica BM, Kadakia MB, de Lemos JA, Roe MT, Morrow DA, Li S, Wiviott SD, Kontos MC. Association between Natriuretic Peptides and Mortality among Patients Admitted with Myocardial Infarction: A Report from the ACTION Registry(R)-GWTG™. Clin Chem. 2013 Aug; 59(8):1205-14.
    View in: PubMed
  14. Mogabgab O, Wiviott SD, Antman EM, Foody JM, Wang TY, Sabatine MS, Cannon CP, Li S, Giugliano RP. Relation Between Time of Symptom Onset of ST-Segment Elevation Myocardial Infarction and Patient Baseline Characteristics: From the National Cardiovascular Data Registry. Clin Cardiol. 2013 Apr; 36(4):222-7.
    View in: PubMed
  15. Steg PG, Mehta SR, Pollack CV, Bode C, Gaudin C, Fanouillere K, Moryusef A, Wiviott SD, Sabatine MS. Design and rationale of the Treatment of Acute Coronary Syndromes with Otamixaban trial: A double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non-ST-segment elevation acute coronary syndromes with a planned early invasive strategy. Am Heart J. 2012 Dec; 164(6):817-824.e13.
    View in: PubMed
  16. Mogabgab O, Giugliano RP, Sabatine MS, Cannon CP, Mohanavelu S, Wiviott SD, Antman EM, Braunwald E. Circadian Variation in Patient Characteristics and Outcomes in ST-Segment Elevation Myocardial Infarction. Chronobiol Int. 2012 Dec; 29(10):1390-6.
    View in: PubMed
  17. Shah RV, Holmes D, Anderson M, Wang TY, Kontos MC, Wiviott SD, M Scirica B. Risk of Heart Failure Complication During Hospitalization for Acute Myocardial Infarction in a Contemporary Population: Insights From the National Cardiovascular Data ACTION Registry. Circ Heart Fail. 2012 Nov 1; 5(6):693-702.
    View in: PubMed
  18. Vavalle JP, Lopes RD, Chen AY, Newby LK, Wang TY, Shah BR, Ho PM, Wiviott SD, Peterson ED, Roe MT, Granger CB. Hospital Length of Stay in Patients with Non-ST-segment Elevation Myocardial Infarction. Am J Med. 2012 Nov; 125(11):1085-94.
    View in: PubMed
  19. Hoffmann U, Truong QA, Schoenfeld DA, Chou ET, Woodard PK, Nagurney JT, Pope JH, Hauser TH, White CS, Weiner SG, Kalanjian S, Mullins ME, Mikati I, Peacock WF, Zakroysky P, Hayden D, Goehler A, Lee H, Gazelle GS, Wiviott SD, Fleg JL, Udelson JE. Coronary CT angiography versus standard evaluation in acute chest pain. N Engl J Med. 2012 Jul 26; 367(4):299-308.
    View in: PubMed
  20. O'Donoghue ML, Bhatt DL, Flather MD, Goto S, Angiolillo DJ, Goodman SG, Zeymer U, Aylward PE, Montalescot G, Ziecina R, Kobayashi H, Ren F, Wiviott SD. Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD program. J Thromb Thrombolysis. 2012 Jul; 34(1):36-43.
    View in: PubMed
  21. Maddox TM, Ho PM, Tsai TT, Wang TY, Li S, Peng SA, Wiviott SD, Masoudi FA, Rumsfeld JS. Clopidogrel use and hospital quality in medically managed patients with non-ST-segment-elevation myocardial infarction. Circ Cardiovasc Qual Outcomes. 2012 Jul 1; 5(4):523-31.
    View in: PubMed
  22. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012 Apr 12; 366(15):1404-13.
    View in: PubMed
  23. Chin CT, Wang TY, Li S, Wiviott SD, deLemos JA, Kontos MC, Peterson ED, Roe MT. Comparison of the prognostic value of peak creatine kinase-MB and troponin levels among patients with acute myocardial infarction: a report from the Acute Coronary Treatment and Intervention Outcomes Network Registry-get with the guidelines. Clin Cardiol. 2012; 35(7):424-9.
    View in: PubMed
  24. Hoffmann U, Truong QA, Fleg JL, Goehler A, Gazelle S, Wiviott S, Lee H, Udelson JE, Schoenfeld D. Design of the Rule Out Myocardial Ischemia/Infarction Using Computer Assisted Tomography: a multicenter randomized comparative effectiveness trial of cardiac computed tomography versus alternative triage strategies in patients with acute chest pain in the emergency department. Am Heart J. 2012 Mar; 163(3):330-8, 338.e1.
    View in: PubMed
  25. Subherwal S, Peterson ED, Chen AY, Roe MT, Washam JB, Gage BF, Bach RG, Bhatt DL, Wiviott SD, Lopes RD, Alexander KP, Wang TY. Admission international normalized ratio levels, early treatment strategies, and major bleeding risk among non-ST-segment-elevation myocardial infarction patients on home warfarin therapy: insights from the National Cardiovascular Data Registry. Circulation. 2012 Mar 20; 125(11):1414-23.
    View in: PubMed
  26. Bonaca MP, Wiviott SD, Braunwald E, Murphy SA, Ruff CT, Antman EM, Morrow DA. American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38). Circulation. 2012 Jan 31; 125(4):577-83.
    View in: PubMed
  27. Fox CS, Muntner P, Chen AY, Alexander KP, Roe MT, Wiviott SD. Short-term outcomes of acute myocardial infarction in patients with acute kidney injury: a report from the national cardiovascular data registry. Circulation. 2012 Jan 24; 125(3):497-504.
    View in: PubMed
  28. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012 Jan 5; 366(1):9-19.
    View in: PubMed
  29. Wiviott SD, Hochholzer W. On-clopidogrel platelet reactivity: a target in sight? J Am Coll Cardiol. 2011 Nov 1; 58(19):1955-7.
    View in: PubMed
  30. Melloni C, Roe MT, Chen AY, Wang TY, Wiviott SD, Ho PM, Peterson ED, Alexander KP. Use of early clopidogrel by reperfusion strategy among patients presenting with ST-segment elevation myocardial infarction. Circ Cardiovasc Qual Outcomes. 2011 Nov 1; 4(6):603-9.
    View in: PubMed
  31. Hanna EB, Chen AY, Roe MT, Wiviott SD, Fox CS, Saucedo JF. Characteristics and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction and chronic kidney disease undergoing percutaneous coronary intervention. JACC Cardiovasc Interv. 2011 Sep; 4(9):1002-8.
    View in: PubMed
  32. Hochholzer W, Trenk D, Mega JL, Morath T, Stratz C, Valina CM, O'Donoghue ML, Bernlochner I, Contant CF, Guo J, Sabatine MS, Schömig A, Neumann FJ, Kastrati A, Wiviott SD, Sibbing D. Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy. Am Heart J. 2011 Sep; 162(3):518-26.e5.
    View in: PubMed
  33. Wiviott SD, Desai N, Murphy SA, Musumeci G, Ragosta M, Antman EM, Braunwald E. Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies. Am J Cardiol. 2011 Oct 1; 108(7):905-11.
    View in: PubMed
  34. Wiviott SD. ILLUMINATE sheds more light. Circulation. 2011 Aug 2; 124(5):536-7.
    View in: PubMed
  35. Frelinger AL, Michelson AD, Wiviott SD, Trenk D, Neumann FJ, Miller DL, Jakubowski JA, Costigan TM, McCabe CH, Antman EM, Braunwald E. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thromb Haemost. 2011 Aug; 106(2):219-26.
    View in: PubMed
  36. Mathews R, Peterson ED, Li S, Roe MT, Glickman SW, Wiviott SD, Saucedo JF, Antman EM, Jacobs AK, Wang TY. Use of emergency medical service transport among patients with ST-segment-elevation myocardial infarction: findings from the National Cardiovascular Data Registry Acute Coronary Treatment Intervention Outcomes Network Registry-Get With The Guidelines. Circulation. 2011 Jul 12; 124(2):154-63.
    View in: PubMed
  37. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011 Jun 14; 123(23):2736-47.
    View in: PubMed
  38. Hochholzer W, Wiviott SD, Antman EM, Contant CF, Guo J, Giugliano RP, Dalby AJ, Montalescot G, Braunwald E. Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation. 2011 Jun 14; 123(23):2681-9.
    View in: PubMed
  39. Wilson SR, Sabatine MS, Wiviott SD, Ray KK, De Lemos JA, Zhou S, Rifai N, Cannon CP, Morrow DA. Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22). Am Heart J. 2011 Jun; 161(6):1147-55.e1.
    View in: PubMed
  40. Wiviott SD, Flather MD, O'Donoghue ML, Goto S, Fitzgerald DJ, Cura F, Aylward P, Guetta V, Dudek D, Contant CF, Angiolillo DJ, Bhatt DL. Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial. Circulation. 2011 May 3; 123(17):1854-63.
    View in: PubMed
  41. O'Donoghue ML, Bhatt DL, Wiviott SD, Goodman SG, Fitzgerald DJ, Angiolillo DJ, Goto S, Montalescot G, Zeymer U, Aylward PE, Guetta V, Dudek D, Ziecina R, Contant CF, Flather MD. Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial. Circulation. 2011 May 3; 123(17):1843-53.
    View in: PubMed
  42. Don CW, Roe MT, Li S, Fraulo E, Pomerantsev E, Palacios I, Wiviott SD. Temporal trends and practice variations in clopidogrel loading doses in patients with non-ST-segment elevation myocardial infarction, from the National Cardiovascular Data Registry. Am Heart J. 2011 Apr; 161(4):689-97.
    View in: PubMed
  43. Britton KA, Aggarwal V, Chen AY, Alexander KP, Amsterdam E, Fraulo E, Muntner P, Thomas L, McGuire DK, Wiviott SD, Roe MT, Schubart UK, Fox CS. No association between hemoglobin A1c and in-hospital mortality in patients with diabetes and acute myocardial infarction. Am Heart J. 2011 Apr; 161(4):657-663.e1.
    View in: PubMed
  44. Abtahian F, Olenchock B, Ou FS, Kontos MC, Saucedo JF, Scirica BM, Desai N, Peterson E, Roe M, Cannon CP, Wiviott SD. Effect of prior stroke on the use of evidence-based therapies and in-hospital outcomes in patients with myocardial infarction (from the NCDR ACTION GWTG registry). Am J Cardiol. 2011 May 15; 107(10):1441-6.
    View in: PubMed
  45. Desai NR, Beckman J, Wiviott SD. When stable becomes unstable: the perils of impersonal medicine. Circulation. 2011 Jan 25; 123(3):335-41.
    View in: PubMed
  46. Mauri L, Kereiakes DJ, Normand SL, Wiviott SD, Cohen DJ, Holmes DR, Bangalore S, Cutlip DE, Pencina M, Massaro JM. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J. 2010 Dec; 160(6):1035-41, 1041.e1.
    View in: PubMed
  47. Ruff CT, Giugliano RP, Antman EM, Murphy SA, Lotan C, Heuer H, Merkely B, Baracioli L, Schersten F, Seabro-Gomes R, Braunwald E, Wiviott SD. Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world. Int J Cardiol. 2012 Mar 22; 155(3):424-9.
    View in: PubMed
  48. Forman DE, Chen AY, Wiviott SD, Wang TY, Magid DJ, Alexander KP. Comparison of outcomes in patients aged <75, 75 to 84, and = 85 years with ST-elevation myocardial infarction (from the ACTION Registry-GWTG). Am J Cardiol. 2010 Nov 15; 106(10):1382-8.
    View in: PubMed
  49. Wiviott SD, Mega JL. Another step on the road to tailored antiplatelet therapy. J Am Coll Cardiol. 2010 Nov 9; 56(20):1637-8.
    View in: PubMed
  50. Kadakia MB, Desai NR, Alexander KP, Chen AY, Foody JM, Cannon CP, Wiviott SD, Scirica BM. Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry--GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry--Get With the Guidelines). JACC Cardiovasc Interv. 2010 Nov; 3(11):1166-77.
    View in: PubMed
  51. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010 Oct 27; 304(16):1821-30.
    View in: PubMed
  52. Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, Antman EM, Braunwald E, Sabatine MS. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010 Oct 16; 376(9749):1312-9.
    View in: PubMed
  53. Pride YB, Tung P, Mohanavelu S, Zorkun C, Wiviott SD, Antman EM, Giugliano R, Braunwald E, Gibson CM. Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) substudy. JACC Cardiovasc Interv. 2010 Aug; 3(8):806-11.
    View in: PubMed
  54. Wiviott SD, Antman EM, Braunwald E. Prasugrel. Circulation. 2010 Jul 27; 122(4):394-403.
    View in: PubMed
  55. Wiviott SD, Antman EM, Braunwald E. Mortality in the TRITON trial: update from the FDA prasugrel action package. Am J Cardiol. 2010 Jul 15; 106(2):293-4.
    View in: PubMed
  56. Diercks DB, Owen KP, Kontos MC, Blomkalns A, Chen AY, Miller C, Wiviott S, Peterson ED. Gender differences in time to presentation for myocardial infarction before and after a national women's cardiovascular awareness campaign: a temporal analysis from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress ADverse Outcomes with Early Implementation (CRUSADE) and the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get with the Guidelines (NCDR ACTION Registry-GWTG). Am Heart J. 2010 Jul; 160(1):80-87.e3.
    View in: PubMed
  57. Lopes RD, Peterson ED, Chen AY, Roe MT, Wang TY, Ohman EM, Magid DJ, Ho PM, Wiviott SD, Scirica BM, Alexander KP. Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. JACC Cardiovasc Interv. 2010 Jun; 3(6):669-77.
    View in: PubMed
  58. Fox CS, Muntner P, Chen AY, Alexander KP, Roe MT, Cannon CP, Saucedo JF, Kontos MC, Wiviott SD. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation. 2010 Jan 26; 121(3):357-65.
    View in: PubMed
  59. Harkness JR, Sabatine MS, Braunwald E, Morrow DA, Sloan S, Wiviott SD, Giugliano RP, Antman EM, Cannon CP, Scirica BM. Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction. Am Heart J. 2010 Jan; 159(1):55-62.
    View in: PubMed
  60. Mahoney EM, Wang K, Arnold SV, Proskorovsky I, Wiviott S, Antman E, Braunwald E, Cohen DJ. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation. 2010 Jan 5; 121(1):71-9.
    View in: PubMed
  61. Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol. 2009 Dec 15; 54(25):2358-62.
    View in: PubMed
  62. Pride YB, Wiviott SD, Buros JL, Zorkun C, Tariq MU, Antman EM, Braunwald E, Gibson CM. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy. Am Heart J. 2009 Sep; 158(3):e21-6.
    View in: PubMed
  63. O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, Michelson AD, Hautvast RW, Ver Lee PN, Close SL, Shen L, Mega JL, Sabatine MS, Wiviott SD. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009 Sep 19; 374(9694):989-97.
    View in: PubMed
  64. O'Donoghue M, Antman EM, Braunwald E, Murphy SA, Steg PG, Finkelstein A, Penny WF, Fridrich V, McCabe CH, Sabatine MS, Wiviott SD. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. J Am Coll Cardiol. 2009 Aug 18; 54(8):678-85.
    View in: PubMed
  65. Giraldez RR, Wiviott SD, Nicolau JC, Mohanavelu S, Morrow DA, Antman EM, Giugliano RP. Streptokinase and enoxaparin as an alternative to fibrin-specific lytic-based regimens: an ExTRACT-TIMI 25 analysis. Drugs. 2009 Jul 30; 69(11):1433-43.
    View in: PubMed
  66. Wrishko RE, Ernest CS, Small DS, Li YG, Weerakkody GJ, Riesmeyer JR, Macias WL, Rohatagi S, Salazar DE, Antman EM, Wiviott SD, Braunwald E, Ni L. Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. J Clin Pharmacol. 2009 Aug; 49(8):984-98.
    View in: PubMed
  67. Morrow DA, Wiviott SD, White HD, Nicolau JC, Bramucci E, Murphy SA, Bonaca MP, Ruff CT, Scirica BM, McCabe CH, Antman EM, Braunwald E. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation. 2009 Jun 2; 119(21):2758-64.
    View in: PubMed
  68. Michelson AD, Frelinger AL, Braunwald E, Downey WE, Angiolillo DJ, Xenopoulos NP, Jakubowski JA, Li Y, Murphy SA, Qin J, McCabe CH, Antman EM, Wiviott SD. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J. 2009 Jul; 30(14):1753-63.
    View in: PubMed
  69. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias WL, Braunwald E, Sabatine MS. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009 May 19; 119(19):2553-60.
    View in: PubMed
  70. Wiviott SD, Mohanavelu S, Raichlen JS, Cain VA, Nissen SE, Libby P. Safety and efficacy of achieving very low low-density lipoprotein cholesterol levels with rosuvastatin 40 mg daily (from the ASTEROID Study). Am J Cardiol. 2009 Jul 1; 104(1):29-35.
    View in: PubMed
  71. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009 Feb 28; 373(9665):723-31.
    View in: PubMed
  72. Truong QA, Cannon CP, Zakai NA, Rogers IS, Giugliano RP, Wiviott SD, McCabe CH, Morrow DA, Braunwald E. Thrombolysis in Myocardial Infarction (TIMI) Risk Index predicts long-term mortality and heart failure in patients with ST-elevation myocardial infarction in the TIMI 2 clinical trial. Am Heart J. 2009 Apr; 157(4):673-9.e1.
    View in: PubMed
  73. Tung P, Wiviott SD, Cannon CP, Murphy SA, McCabe CH, Gibson CM. Seasonal variation in lipids in patients following acute coronary syndrome on fixed doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 [PROVE IT-TIMI 22] Study). Am J Cardiol. 2009 Apr 15; 103(8):1056-60.
    View in: PubMed
  74. Diercks DB, Kontos MC, Chen AY, Pollack CV, Wiviott SD, Rumsfeld JS, Magid DJ, Gibler WB, Cannon CP, Peterson ED, Roe MT. Utilization and impact of pre-hospital electrocardiograms for patients with acute ST-segment elevation myocardial infarction: data from the NCDR (National Cardiovascular Data Registry) ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. J Am Coll Cardiol. 2009 Jan 13; 53(2):161-6.
    View in: PubMed
  75. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009 Jan 22; 360(4):354-62.
    View in: PubMed
  76. Wiviott SD. Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel? Cardiol Clin. 2008 Nov; 26(4):629-37.
    View in: PubMed
  77. Stephen D Wiviott (Editor). Antiplatelet Therapy in Ischemic Heart Disease, Stephen D. Wiviott (Editor). 2008.
  78. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, Goodman SG, Corbalan R, Purdy DA, Murphy SA, McCabe CH, Antman EM. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation. 2008 Oct 14; 118(16):1626-36.
    View in: PubMed
  79. Murphy SA, Antman EM, Wiviott SD, Weerakkody G, Morocutti G, Huber K, Lopez-Sendon J, McCabe CH, Braunwald E. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J. 2008 Oct; 29(20):2473-9.
    View in: PubMed
  80. Brilakis ES, de Lemos JA, Cannon CP, Wiviott SD, Murphy SA, Morrow DA, Sabatine MS, Banerjee S, Blazing MA, Califf RM, Braunwald E. Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials). Am J Cardiol. 2008 Sep 1; 102(5):552-8.
    View in: PubMed
  81. Antman EM, Wiviott SD, Murphy SA, Voitk J, Hasin Y, Widimsky P, Chandna H, Macias W, McCabe CH, Braunwald E. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol. 2008 May 27; 51(21):2028-33.
    View in: PubMed
  82. Wiviott SD, Braunwald E, McCabe CH, Horvath I, Keltai M, Herrman JP, Van de Werf F, Downey WE, Scirica BM, Murphy SA, Antman EM. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet. 2008 Apr 19; 371(9621):1353-63.
    View in: PubMed
  83. Wiviott SD, Braunwald E, Murphy SA, Antman EM. A perspective on the efficacy and safety of intensive antiplatelet therapy in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Am J Cardiol. 2008 May 1; 101(9):1367-70.
    View in: PubMed
  84. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I17-20.
    View in: PubMed
  85. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. Antiplatelet therapy and platelet function testing. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I36.
    View in: PubMed
  86. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I2-9.
    View in: PubMed
  87. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. Assessing the current role of platelet function testing. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I10-6.
    View in: PubMed
  88. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. Antiplatelet therapy and platelet function testing. Introduction. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I1.
    View in: PubMed
  89. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I28-35.
    View in: PubMed
  90. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. Investigating the mechanisms of hyporesponse to antiplatelet approaches. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I21-7.
    View in: PubMed
  91. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007 Dec 18; 116(25):2923-32.
    View in: PubMed
  92. de Lemos JA, Morrow DA, Blazing MA, Jarolim P, Wiviott SD, Sabatine MS, Califf RM, Braunwald E. Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. J Am Coll Cardiol. 2007 Nov 27; 50(22):2117-24.
    View in: PubMed
  93. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007 Nov 15; 357(20):2001-15.
    View in: PubMed
  94. Ruff CT, Wiviott SD, Morrow DA, Mohanavelu S, Murphy SA, Antman EM, Braunwald E. TIMI risk index and the benefit of enoxaparin in patients with ST-elevation myocardial infarction. Am J Med. 2007 Nov; 120(11):993-8.
    View in: PubMed
  95. Wiviott SD and Giugliano RP. Unstable Angina and Non-ST Elevation Myocardial Infarction. Cardiovascular Therapeutics. A Companion to Braunwald's Heart Disease. EM Antman, Editor. 2007; 221-245.
  96. Yeh RW, Wiviott SD, Giugliano RP, Morrow DA, Shui A, Qin J, Scirica B, Bradner JE, Jang IK, Gibson CM, Antman EM. Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes. Am J Cardiol. 2007 Dec 15; 100(12):1734-8.
    View in: PubMed
  97. Olenchock BA, Wiviott SD, Murphy SA, Cannon CP, Rifai N, Braunwald E, Morrow DA. Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16. J Thromb Thrombolysis. 2008 Oct; 26(2):79-84.
    View in: PubMed
  98. Wiviott SD, de Lemos JA. Antiplatelet agents make a comeback in ST-elevation myocardial infarction. Am Heart J. 2007 Oct; 154(4):603-6.
    View in: PubMed
  99. Scirica BM, Morrow DA, Cannon CP, de Lemos JA, Murphy S, Sabatine MS, Wiviott SD, Rifai N, McCabe CH, Braunwald E. Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. Clin Chem. 2007 Oct; 53(10):1800-7.
    View in: PubMed
  100. Murphy SA, Cannon CP, Wiviott SD, de Lemos JA, Blazing MA, McCabe CH, Califf RM, Braunwald E. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials). Am J Cardiol. 2007 Oct 1; 100(7):1047-51.
    View in: PubMed
  101. Rich JD, Wiviott SD. New antiplatelet therapies for acute coronary syndromes. Curr Cardiol Rep. 2007 Jul; 9(4):303-11.
    View in: PubMed
  102. Scirica BM, Morrow DA, Sadowski Z, Ruda M, Nicolau JC, Giugliano RP, Wiviott SD, Sabatine MS, Shui A, Antman EM, Braunwald E. A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study. Eur Heart J. 2007 Sep; 28(17):2070-6.
    View in: PubMed
  103. Giugliano RP, Wiviott SD, Stone PH, Simon DI, Schweiger MJ, Bouchard A, Leesar MA, Goulder MA, Deitcher SR, McCabe CH, Braunwald E. Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial. J Am Coll Cardiol. 2007 Jun 26; 49(25):2398-407.
    View in: PubMed
  104. Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS, Jakubowski JA, Naganuma H, Winters KJ. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007 Jan; 153(1):66.e9-16.
    View in: PubMed
  105. Wiviott SD, Cannon CP. The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy. Curr Opin Lipidol. 2006 Dec; 17(6):626-30.
    View in: PubMed
  106. Bonaca MP, Wiviott SD, Sabatine MS, Buros J, Murphy SA, Scirica BM, Rifai N, Antman EM, Morrow DA. Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial). Am J Cardiol. 2007 Feb 1; 99(3):344-8.
    View in: PubMed
  107. O'Donoghue M, Wiviott SD. Clopidogrel response variability and future therapies: clopidogrel: does one size fit all? Circulation. 2006 Nov 28; 114(22):e600-6.
    View in: PubMed
  108. Wiviott SD, Morrow DA, Sabatine MS, Giugliano GR, Guo W, Jarolim P, Gibson CM, Cannon CP, Braunwald E. Baseline Cystatin C Measurement is a Potent Predictor of Adverse Cardiovascular Outcomes Following ACS: A PROVE IT - TIMI 22 Analysis. Circulation. 2006; 114(18 Supplement II):418.
  109. Ruff CT, Wiviott SD, Antman EM, Shui A, McCabe CH, Morrow DA. Effect of Risk on the Benefit of Enoxaparin versus Unfractionated Heparin in Patients with ST-Elevation Myocardial Infarction in the ExTRACT - TIMI 25 Trial. Circulation. 2006; 114(18 Supplement II):814.
  110. Wiviott SD, Stone PH, Bouchard A, Alshaher, Goulder MA, Deitcher SR, Giuglaino RP on Behalf of the ANTHEM - TIMI 32 Investigators. F1.2 Correlates with Ischemia by Holter Monitoring and Is Suppressed by rNAPc2: an ANTHEM - TIMI 32 Biomarker Analysis. Circulation. 2006; 114(18 Supplement II):462.
  111. de Lemos JA, Morrow DA, Wiviott SD, Jarolim P, Blazing MA, Shui A, Sabatine MS, Callif RM, Braunwald E. Evaluation of Monocyte Chemoattractant Protein 1 as a Prognostic Marker in the A to Z Trial. Circulation. 2006; 114(18 Supplement II):648.
  112. Bonaca MP, Wiviott SD, Sabatine MS, Murphy SA, Scirica BM, Rifai N, Antman EM, Morrow DA. Hemodynamic significance of peri-procedural MI after percutaneous intervention: A TIMI 26 substudy. Circulation. 2006; 112(17 (Supplement II)):694.
  113. Wiviott SD, Antman EM, Gibson CM, Montalescot G, Riesmeyer J, Weerakkody G, Winters KJ, Warmke JW, McCabe CH, Braunwald E. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J. 2006 Oct; 152(4):627-35.
    View in: PubMed
  114. Wiviott SD. Clopidogrel response variability, resistance, or both? Am J Cardiol. 2006 Nov 20; 98(10A):18N-24N.
    View in: PubMed
  115. Ray KK, Bach RG, Cannon CP, Cairns R, Kirtane AJ, Wiviott SD, McCabe CH, Braunwald E, Gibson CM. Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. Eur Heart J. 2006 Oct; 27(19):2310-6.
    View in: PubMed
  116. Wiviott SD, Cannon CP. Update on lipid-lowering therapy and LDL-cholesterol targets. Nat Clin Pract Cardiovasc Med. 2006 Aug; 3(8):424-36.
    View in: PubMed
  117. de Lemos JA, Wiviott SD, Murphy SA, Blazing MA, Lewis EF, Califf RM, Pfeffer MA, Braunwald E. Evaluation of the National Cholesterol Education Program Adult Treatment Panel III algorithm for selecting candidates for statin therapy: insights from the A to Z trial. Am J Cardiol. 2006 Sep 15; 98(6):739-42.
    View in: PubMed
  118. Morrow DA, de Lemos JA, Sabatine MS, Wiviott SD, Blazing MA, Shui A, Rifai N, Califf RM, Braunwald E. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation. 2006 Jul 25; 114(4):281-8.
    View in: PubMed
  119. Scirica BM, Sabatine MS, Morrow DA, Gibson CM, Murphy SA, Wiviott SD, Giugliano RP, McCabe CH, Cannon CP, Braunwald E. The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study. J Am Coll Cardiol. 2006 Jul 4; 48(1):37-42.
    View in: PubMed
  120. Wiviott SD, Morrow DA, Frederick PD, Antman EM, Braunwald E. Application of the Thrombolysis in Myocardial Infarction risk index in non-ST-segment elevation myocardial infarction: evaluation of patients in the National Registry of Myocardial Infarction. J Am Coll Cardiol. 2006 Apr 18; 47(8):1553-8.
    View in: PubMed
  121. Wiviott SD, de Lemos JA, Cannon CP, Blazing M, Murphy SA, McCabe CH, Califf R, Braunwald E. A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation. 2006 Mar 21; 113(11):1406-14.
    View in: PubMed
  122. O'Donoghue M, Sabatine MS, Wiviott SD, Murphy SA, McCabe CH, Cannon CP, Braunwald E. Association of TIMI risk score and extent of coronary artery disease in patients with ST-elevation myocardial infarction: A CLARITY TIMI-28 substudy. JACC. 2006; 47(4 (Supplement A)):222.
  123. Yeh RW, Wiviott SD, Giugliano RP, Morrow DA, Bradner JE, Jang IK, Gibson CM, Antman EM. Thrombocytopenia is Associated with Adverse Outcomes Following Treatment With Either Enoxaparin or Unfractionated Heparin in Patients Presenting with Acute Coronary Syndromes: A TIMI 11B Substudy. JACC. 2006; 47(4 (Supplement A)):223.
  124. Wiviott SD, Morrow DA, O'Donoghue M, Sabatine MS, Cannon CP, . The TIMI Risk Index for Myocardial Infarction Predicts Post-MI LV Ejection Fraction: A Clarity - TIMI 28 Substudy. JACC. 2006; 47(4 (Supplement A)):224.
  125. Wiviott SD, Tantry US, Gurbel PA. Clinical applications of antiplatelet therapy. Rev Cardiovasc Med. 2006; 7(3):130-46; quiz 148-9.
    View in: PubMed
  126. Wiviott SD, Michelson AD, Berger PB, Lepor NE, Kereiakes DJ. Therapeutic goals for effective platelet inhibition: a consensus document. Rev Cardiovasc Med. 2006; 7(4):214-25.
    View in: PubMed
  127. Wiviott SD, Morrow DA, Sabatine MS, Murphy SA, Winters KJ, Antman EM, Braunwald E. Prasugrel Suppresses the Early Rise of sCD40 Ligand Levels Following PCI Compared to Clopidogrel: A JUMBO - TIMI 26 Substudy. Circulation. 2005; 112(17 (Supplement II) ):432.
  128. Morrow DA, de Lemos JA, Wiviott SD, Blazing MA, Sabatine MS, Rifai N, Califf R, Braunwald E. Clinical Relevance of C-Reactive Protein During Follow-Up of Patients with ACS treated with Statin Therapy: An A to Z Substudy. Circulation. 2005; 112(17 (Supplement II)):387.
  129. Bonaca MP, Morrow DA, Wiviott SD, Sabatine MS, Murphy SA, Scirica BM, Rifai N, Antman EM, Braunwald E. Clinical Correlates and Impact of Aspirin on the Inflammatory Response to Percutaneous Coronary Intervention: Results from TIMI 26. Circulation. 2005; 112(17 (Supplement 2)):322.
  130. Scirica BM, Sabatine MS, Morrow DA, Gibson CM, Murphy SA, Wiviott SD, Giugliano RP, McCabe CH, Cannon CP, Braunwald E. Correlates and outcomes associated with ST segment resolution after fibrinolytic therapy. Results from the ECG CLARITY - TIMI 28 substudy. Circulation. 2005; 112(17 (Supplement II)):486.
  131. Scirica BM, Sabatine MS, Morrow DA, Wiviott SD, Murphy SA, Giugliano RP, Gibson CM, McCabe CH, Cannon CP, Braunwald E. Clopidogrel Reduces In-Hospital Mortality and Recurrent MI in Pateints with STEMI Undergoing Lysis Who Achieve Early ST Resolution - The ECG CLARITY - TIMI 28 Substudy. Circulation. 2005; 112(17 (Supplement II)):568.
  132. Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol. 2005 Oct 18; 46(8):1411-6.
    View in: PubMed
  133. Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, Carney RJ, Lazzam C, McKay RG, McCabe CH, Braunwald E. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation. 2005 Jun 28; 111(25):3366-73.
    View in: PubMed
  134. Wiviott SD and Morrow DA. The TIMI Risk Index: A Simple Index that Predicts Mortality in ST-Elevation Myocardial Infarction. 2005.
  135. Scirica BS, Murphy SA, Morrow DA, Sabatine MS, Gibson CM, Cannon CP. Chest Pain at Presentation and Delayed Resolution of Pain in Patients admitted with Non-ST Segment Elevation Acute Coronary Sundromes Predicts Short Term Outcomes. JACC. 2005; 45(3):199A.
  136. Brandt JT, Payne CD, Weerakkody G, Behounek BD, Naganuma H, Jakubowski JA, Wiviott SD, Winters KJ. Superior Responder Rate for Inhibition of Platelet Aggregation with a 60 mg Loading Dose of Prasugrel (CS-747, LY640315) Compared With a 300 mg Loading Dose of Clopidogrel. JACC. 2005; 45(3 (Supplement A)):87A.
  137. Wiviott SD, Cannon CP, Ray KK, Murphy SA, Darius, H, Castaigne A, Velasco JA, McCabe CH, Gibson CM. Seasonal Variation in Lipid Values in Pateints Following ACS: PROVE IT - TIMI 22. JACC. 2005; 45(3 (Supplement A)):394 A.
  138. Wiviott SD and Cannon CP. Evaluation and Treatment of Unstable Angina/Non-ST Elevation Myocardial Infarction in the Elderly. Gerstenblith G.(ed.) Cardiovascular Diseases in The Elderly. 2005; 141-157.
  139. Gibson CM, Dumaine RL, Gelfand EV, Murphy SA, Morrow DA, Wiviott SD, Giugliano RP, Cannon CP, Antman EM, Braunwald E. Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials. Eur Heart J. 2004 Nov; 25(22):1998-2005.
    View in: PubMed
  140. de Lemos JA, Blazing MA, Wiviott SD, Brady WE, White HD, Fox KA, Palmisano J, Ramsey KE, Bilheimer DW, Lewis EF, Pfeffer M, Califf RM, Braunwald E. Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial. Eur Heart J. 2004 Oct; 25(19):1688-94.
    View in: PubMed
  141. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004 Sep 15; 292(11):1307-16.
    View in: PubMed
  142. Wiviott SD, Morrow DA, Frederick PD, Giugliano RP, Gibson CM, McCabe CH, Cannon CP, Antman EM, Braunwald E. Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: a simple index that predicts mortality in ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004 Aug 18; 44(4):783-9.
    View in: PubMed
  143. Wiviott SD, de Lemos JA, Morrow DA. Pathophysiology, prognostic significance and clinical utility of B-type natriuretic peptide in acute coronary syndromes. Clin Chim Acta. 2004 Aug 16; 346(2):119-28.
    View in: PubMed
  144. Wiviott SD, Braunwald E. Unstable angina and non-ST-segment elevation myocardial infarction: part I. Initial evaluation and management, and hospital care. Am Fam Physician. 2004 Aug 1; 70(3):525-32.
    View in: PubMed
  145. Wiviott SD, Braunwald E. Unstable angina and non-ST-segment elevation myocardial infarction: part II. Coronary revascularization, hospital discharge, and post-hospital care. Am Fam Physician. 2004 Aug 1; 70(3):535-8.
    View in: PubMed
  146. Wiviott SD, Antman EM. Clopidogrel resistance: a new chapter in a fast-moving story. Circulation. 2004 Jun 29; 109(25):3064-7.
    View in: PubMed
  147. Wiviott SD, Cannon CP, Morrow DA, Murphy SA, Gibson CM, McCabe CH, Sabatine MS, Rifai N, Giugliano RP, DiBattiste PM, Demopoulos LA, Antman EM, Braunwald E. Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy. Circulation. 2004 Feb 10; 109(5):580-6.
    View in: PubMed
  148. Gibson CM, Pinto DS, Murphy SA, Morrow DA, Hobbach HP, Wiviott SD, Giugliano RP, Cannon CP, Antman EM, Braunwald E. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol. 2003 Nov 5; 42(9):1535-43.
    View in: PubMed
  149. Nass CM, Wiviott SD, Allen JK, Post WS, Blumenthal aR. Global risk assessment for lipid therapy to prevent coronary heart disease. Curr Cardiol Rep. 2000 Sep; 2(5):424-32.
    View in: PubMed
  150. Jeron A, Mitchell GF, Zhou J, Murata M, London B, Buckett P, Wiviott SD, Koren G. Inducible polymorphic ventricular tachyarrhythmias in a transgenic mouse model with a long Q-T phenotype. Am J Physiol Heart Circ Physiol. 2000 Jun; 278(6):H1891-8.
    View in: PubMed
  151. Kaye DM, Wiviott SD, Kelly RA. Activation of nitric oxide synthase (NOS3) by mechanical activity alters contractile activity in a Ca2+-independent manner in cardiac myocytes: role of troponin I phosphorylation. Biochem Biophys Res Commun. 1999 Mar 16; 256(2):398-403.
    View in: PubMed
  152. Kaye DM, Wiviott SD, Kobzik L, Kelly RA, Smith TW. S-nitrosothiols inhibit neuronal norepinephrine transport. Am J Physiol. 1997 Feb; 272(2 Pt 2):H875-83.
    View in: PubMed
  153. Smith TW, Balligand JL, Kaye DM, Wiviott SD, Simmons WW, Han X, Michel T, Singh K, Kelly RA. The role of the NO pathway in the control of cardiac function. J Card Fail. 1996 Dec; 2(4 Suppl):S141-7.
    View in: PubMed
  154. Wiviott SD and Smith TW. Inhibition of Nitric Oxide Signalling in Adult Rat Ventricular Myocytes Increases Contractile Function in a Calcium-Independent Manner. 1996.
  155. Kaye DM, Wiviott SD, Balligand JL, Simmons WW, Smith TW, Kelly RA. Frequency-dependent activation of a constitutive nitric oxide synthase and regulation of contractile function in adult rat ventricular myocytes. Circ Res. 1996 Feb; 78(2):217-24.
    View in: PubMed
  156. Wehrenberg WB, Wiviott SD, Voltz DM, Giustina A. Pyridostigmine-mediated growth hormone release: evidence for somatostatin involvement. Endocrinology. 1992 Mar; 130(3):1445-50.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Wiviott's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_